Treatment Approach for Heavy Menstrual Bleeding in a 47-Year-Old Perimenopausal Woman with Normal Hormonal Labs
The levonorgestrel-releasing intrauterine system (LNG-IUS) should be your first-line treatment, as it provides the most effective reduction in menstrual blood loss with minimal systemic effects and is comparable in efficacy to endometrial ablation or hysterectomy for this patient population 1, 2.
Initial Evaluation Requirements
Before initiating treatment, you must:
- Exclude structural pathology: Perform transvaginal ultrasound to rule out endometrial polyps, fibroids, or endometrial hyperplasia/malignancy 3
- Check hemoglobin and ferritin levels: Assess for anemia and iron deficiency, which are common with heavy menstrual bleeding 4
- Rule out pregnancy: Measure β-hCG if any possibility exists
- Consider endometrial sampling: If ultrasound shows thickened endometrium (>4mm in perimenopause) or if bleeding pattern has changed substantially 3, 5
Treatment Algorithm
First-Line Medical Options (in order of effectiveness):
1. Levonorgestrel Intrauterine System (LNG-IUS) - MOST EFFECTIVE
- Reduces menstrual blood loss by 86-97% 2, 5
- Efficacy comparable to endometrial ablation and hysterectomy 6, 7
- Provides endometrial protection with minimal systemic absorption 1
- Particularly appropriate for perimenopausal women as it will carry them through to menopause 3
- Evidence rating: Category 1 for heavy menstrual bleeding 2
2. Tranexamic Acid
- Reduces menstrual blood loss by 40-60% 5
- Non-hormonal option, taken only during menses (typically 1-1.3g three times daily for up to 5 days) 6, 7
- Excellent choice if hormonal therapy is contraindicated or declined
3. NSAIDs (Mefenamic Acid or Ibuprofen)
- Reduces menstrual blood loss by 20-30% 5
- Take during menses only
- Less effective than LNG-IUS or tranexamic acid but useful for mild cases
4. Combined Oral Contraceptives or Progestogens
- Combined hormonal contraceptives can be used if no contraindications exist 3
- Cyclic progestogens (e.g., medroxyprogesterone acetate 5-10mg for 10-12 days/month) for luteal phase supplementation in irregular cycles 1
- Important caveat: Cyclic progestogens do NOT significantly reduce bleeding in women who ovulate regularly 5
Critical Clinical Pitfalls
Do NOT start with cyclic progestogens alone if the patient has regular ovulatory cycles—they are ineffective for reducing menstrual blood loss in this scenario 5. They are only useful for anovulatory bleeding or endometrial protection.
Do NOT delay structural evaluation: Perimenopausal women have increased risk of endometrial polyps and fibroids, which peak in this age group 3. Missing structural pathology leads to treatment failure.
Do NOT assume hormonal dysfunction: Since her hormonal labs are normal, this suggests she may still be ovulating regularly. The bleeding is likely structural (polyps, fibroids) or related to local endometrial factors rather than hormonal imbalance 3.
When Medical Management Fails
If medical therapy is ineffective after 3-6 months or if structural lesions are identified:
- Hysteroscopic polypectomy or myomectomy for focal lesions 3
- Endometrial ablation for women with completed fertility and normal endometrial cavity 8, 3
- Hysterectomy as definitive treatment if other options fail or are declined 8
Special Consideration for This Patient
At age 47, this patient is likely within 3-5 years of menopause. The LNG-IUS is particularly advantageous because it will provide effective bleeding control through the perimenopausal transition and into menopause 1, 3. Natural menopause will resolve the bleeding issue, making this a time-limited problem that doesn't necessarily require permanent surgical intervention.
The LNG-IUS also protects against endometrial hyperplasia if she develops anovulatory cycles as she approaches menopause 1, and it can be used for endometrial protection if she later requires systemic estrogen therapy for vasomotor symptoms 1.